RayKnowChina Research Map
Shortlist

RecruitingGliomaN/A

Registered title, quoted from ClinicalTrials.gov

Recurrent High Grade Glioma Treated by LITT

An open trial on glioma, registered on ClinicalTrials.gov. Led by Beijing Tiantan Hospital; 7 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Patients with previous pathological diagnosis of 2021 World Health Organization Classification of Central Nervous System Tumors (WHO CNS5) grade 3 or 4 glioma and received standard treatment;

    Inclusion criterion 2

    Pathology shows progression or recurrence;

    Inclusion criterion 6

  3. At least one image other than T1 contrast indicates progression;

    Inclusion criterion 5

    All tumor lesions are located supratentorial and the maximum cross-sectional short-axis length in the T1 contrast is ≤30 mm;

    Inclusion criterion 8

  4. Karnofsky score (KPS) ≥ 60 and the patient can tolerate the intervention;

    Inclusion criterion 9

  5. Women who are pregnant, lactating, or planning to become pregnant within 6 months;

    Exclusion criterion 5

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06161610, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Aged 18 years old or above;
  • Patients with previous pathological diagnosis of 2021 World Health Organization Classification of Central Nervous System Tumors (WHO CNS5) grade 3 or 4 glioma and received standard treatment;
  • Meet any of the following:
  • Meets the disease progression criteria in the Response Evaluation of Neuro-Oncology (RANO 2.0) criteria;
  • At least one image other than T1 contrast indicates progression;
  • Pathology shows progression or recurrence;
  • Other progress determined by the Clinical Events Committee (CEC);
  • All tumor lesions are located supratentorial and the maximum cross-sectional short-axis length in the T1 contrast is ≤30 mm;
  • Karnofsky score (KPS) ≥ 60 and the patient can tolerate the intervention;
  • The subjects or their agent can understand the purpose of the trial, show sufficient compliance with the trial protocol, and sign the informed consent form.

Exclusion Criteria:

  • Patients may benefit from other treatments or may not benefit from this trial;
  • No more than three months since the patient underwent craniotomy;
  • MRI contrast cannot be performed;
  • Severe coagulation disorder;
  • Women who are pregnant, lactating, or planning to become pregnant within 6 months;
  • Participated in any other clinical trials of drugs or medical devices within 3 months;
  • Combined diseases that may interfere with treatment or prognosis assessment;
  • Refuse or unlikely to complete follow-up assessment;
  • Other circumstances in which the researcher deems it inappropriate to participate in this clinical trial.

Quoted from ClinicalTrials.gov, NCT06161610, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06161610, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06161610